東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Minimally invasive biomaterials for ...

Rauck, Britta Mary.

FindBook

Google Book

Amazon

博客來

Minimally invasive biomaterials for central nervous system therapies.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Minimally invasive biomaterials for central nervous system therapies./
作者:	Rauck, Britta Mary.
面頁冊數:	155 p.
附註:	Source: Dissertation Abstracts International, Volume: 76-01(E), Section: B.
Contained By:	Dissertation Abstracts International76-01B(E).
標題:	Engineering, Biomedical. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3582605
ISBN:	9781321209419

Minimally invasive biomaterials for central nervous system therapies.
Rauck, Britta Mary.

Minimally invasive biomaterials for central nervous system therapies. - 155 p.

Source: Dissertation Abstracts International, Volume: 76-01(E), Section: B.

Thesis (Ph.D.)--University of Pittsburgh, 2014.

The inability of the adult central nervous system (CNS) to regenerate combined with the progressive nature of many CNS pathologies poses a significant challenge in developing effective treatments. Biomaterials-based systems designed to deliver drugs and/or cells hold immense potential for moderating disease progression and promoting repair. Ideally, such systems should (1) allow minimally invasive administration, (2) provide localized and controlled delivery, and (3) protect the activity of their cargo for maximal therapeutic effect. Additionally, the ability to incorporate multiple treatment modalities is desirable as many CNS disorders are multi-faceted and complex in nature. Designing delivery systems that incorporate these features while simultaneously improving therapeutic outcomes, however, poses a significant challenge. This dissertation covers the formulation and application of polymer-based delivery systems for CNS repair, with specific focus given to the spinal cord and visual systems.

ISBN: 9781321209419Subjects--Topical Terms:

1017684
Engineering, Biomedical.

Minimally invasive biomaterials for central nervous system therapies.
LDR:02966nam a2200301 4500 001 1967058
005 20141112075754.5
008 150210s2014 ||||||||||||||||| ||eng d
020 $a 9781321209419
035 $a (MiAaPQ)AAI3582605
035 $a AAI3582605
040 $a MiAaPQ $c MiAaPQ
100 1 $a Rauck, Britta Mary. $3 2103977
245 1 0 $a Minimally invasive biomaterials for central nervous system therapies.
300 $a 155 p.
500 $a Source: Dissertation Abstracts International, Volume: 76-01(E), Section: B.
500 $a Adviser: Yadong Wang.
502 $a Thesis (Ph.D.)--University of Pittsburgh, 2014.
520 $a The inability of the adult central nervous system (CNS) to regenerate combined with the progressive nature of many CNS pathologies poses a significant challenge in developing effective treatments. Biomaterials-based systems designed to deliver drugs and/or cells hold immense potential for moderating disease progression and promoting repair. Ideally, such systems should (1) allow minimally invasive administration, (2) provide localized and controlled delivery, and (3) protect the activity of their cargo for maximal therapeutic effect. Additionally, the ability to incorporate multiple treatment modalities is desirable as many CNS disorders are multi-faceted and complex in nature. Designing delivery systems that incorporate these features while simultaneously improving therapeutic outcomes, however, poses a significant challenge. This dissertation covers the formulation and application of polymer-based delivery systems for CNS repair, with specific focus given to the spinal cord and visual systems.
520 $a We first demonstrated the biocompatibility and feasibility of a reverse thermal gel, poly(ethylene glycol)--poly(serinol hexamethylene urethane) (ESHU) for intraocular drug delivery. This injectable formulation is capable of sustaining the bevacizumab release in vivo, and ultimately may be used to reduce the injection frequency in patients with ocular diseases such as age-related macular degeneration. To emphasize the versatility of ESHU, it was combined with bone marrow stromal cells (BMSCs) for treatment of traumatic spinal cord injury in rats. ESHU improved BMSC survival 3.5-fold one week post-injury compared to BMSCs injected in PBS, which was accompanied by increased nervous tissue sparing and functional recovery. Finally, we demonstrated the feasibility of a coacervate-based growth factor delivery system for treatment of traumatic spinal cord injury. Ultimately, we hope the coacervate may be used in combination to augment cell therapy and drive the development of innovative solutions to treat injuries for where there are no cures. v.
590 $a School code: 0178.
650 4 $a Engineering, Biomedical. $3 1017684
650 4 $a Engineering, Chemical. $3 1018531
650 4 $a Engineering, General. $3 1020744
690 $a 0541
690 $a 0542
690 $a 0537
710 2 $a University of Pittsburgh. $3 958527
773 0 $t Dissertation Abstracts International $g 76-01B(E).
790 $a 0178
791 $a Ph.D.
792 $a 2014
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3582605